A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1 - Occurrence of dose limiting toxicities (DLTs) within a participant

  Measured over: 21 days starting on Day 1 of Cycle 1

• Part 1 and Part 2a - Occurrence of treatment emergent adverse events (TEAEs), treatment-related adverse events (TRAE), treatment emergent serious adverse events (TESAE), treatment-related serious adverse events (TRSAE)

  Measured over: from the first dose of investigational medicinal product (IMP) up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months)

• Part 1 and Part 2a - Occurrence of dose interruption, reduction, and discontinuation due to TEAEs

  Measured over: from the first dose of IMP up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months)

• Part 2a and Part 2b - Objective response rate (ORR)

  Measured over: from the time of initiation of the first dose of IMP to approximately 36 months

Changes Tremor has spotted